ClinicalTrials.gg
Not yet recruitingNCT06920537Updated May 14, 2025

Postpartum CO Rehabilitation

An interventional study of Postpartum Cardio-obstetric Rehabilitation Program in Gestational Hypertension and Preeclampsia (PE), sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.

Primary conditionPre-EclampsiaRegistry: Hypertension, Pregnancy-InducedReclassifiedWhy we changed it
Registry
Hypertension, Pregnancy-Induced — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pre-Eclampsia
Why
  1. The study's listed conditions name Pre-Eclampsia, a narrower term within Hypertension, Pregnancy-Induced.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Pre-Eclampsia with a site in Canada — 4 open to participants now, 5 under way, 1 of them phase 3. Pre-Eclampsia · Canada.

Planned enrollment
17th of 19
40 · median 73
Started
2025
the only one that year
No phase
11 of 31
1 open now
Registered
31st of 31
by date
Lead sponsor
1 of 31
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

Among the 31 studies in Pre-Eclampsia with a site in Canada, this one is the 17th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 31st registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

4 of the 31 studies in Pre-Eclampsia with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Pre-Eclampsia with a site in Canada, or all of them as a file.
02

Study summary

Some women who develop high blood pressure during pregnancy, such as gestational hypertension or preeclampsia, may continue to have slightly or moderately high blood pressure after giving birth. This can increase their risk of heart disease later in life. Managing blood pressure and adopting a healthy lifestyle after pregnancy could help lower this risk.

Right now, the investigators don't know much about how postpartum rehabilitation programs focused on heart and pregnancy-related health could help women with these conditions. However, a feasibility study suggests that exercise programs might help reduce blood pressure and encourage healthier lifestyles in these women.

In this study, the investigators are testing an 8-week exercise program to see how it affects blood pressure, fitness, and blood vessel health. The investigators will compare the results with a group of women who receive usual healthcare, which includes verbal advice on healthy living but no supervised exercise sessions.

This type of program, called cardio-obstetric rehabilitation, combines exercises for heart health with specialized care for women's health.

Read the detailed description

Women with severe hypertensive disorders during pregnancy, such as preeclampsia (PE), have a higher risk of heart disease and stroke within five to 10 years of their pregnancy. Because their blood pressure (BP) drops in the postpartum period in comparison to the values they had during pregnancy, the hypertensive disorder can be considered resolved. However, recent studies have shown that their postpartum BP may be higher than before pregnancy. Hypertensive pregnancy has been associated with endothelial and microvascular dysfunction and capillary rarefaction, which could be the key mechanism leading to elevated BP in the postpartum period. Studies have shown that physical exercise promotes BP reduction, stimulates angiogenesis and improves microcirculation in healthy subjects, but also in patients with cardiovascular and metabolic diseases. Therefore, interventions to better monitor BP combined with a healthy lifestyle could help reduce the risk of heart disease in later years. The effects of postpartum cardio-obstetric rehabilitation in women with gestational hypertension (GH) or PE are still unknown. It is of interest to determine whether a postpartum cardio-obstetric rehabilitation program could reduce BP, identifying the possible mechanisms, and stimulate the adoption of a healthy lifestyle with potential long-term health benefits for women.

The main objective of this study is to describe the effects of an 8-week rehabilitation program combining aerobic exercise with obstetric rehabilitation starting between 3 to 6 months postpartum on BP changes, vascular structure and physical activity levels, which could lead to long term health benefits compared to usual care in women with previous GH and PE. The 8-week rehabilitation program will include cardiac (aerobic exercise) and obstetric (pelvic floor training, core and balance) exercises, as well as online education courses about healthy lifestyle. The outcomes will be compared with participants submitted to the usual care in the postpartum. At the end of the study participation period, participants of the control group will be offered to participate in the intervention program (crossing study).

The following outcomes will be evaluated, before and immediately after the intervention: ambulatory and 24-hour BP, arterial stiffness, pulse wave velocity, static retinal vessels analysis, body composition (including body mass index), physical capacity (6-minute walk test), physical activity level (number of daily steps), lipid and glucose profiles, quality of life (SF-36), as well as plasmatic angiogenic biomarkers and the angiogenic function of circulating endothelial cells. Moreover, 6-months post-intervention, participants will be submitted again only to physical evaluation to assess the long-term effects of the intervention program.

Cardio-obstetric rehabilitation is a new field, lacking the description and evaluation of effective programs. The investigators expect that the results obtained from this study will contribute to the design of a patient-oriented rehabilitation program. Our findings will provide the first evidence to support postpartum rehabilitation services in clinics which in turn could lead to long term health benefits to women.

03

Conditions studied

  • Gestational Hypertension
  • Preeclampsia (PE)

Browse trials for

Keywords

  • postpartum rehabilitation
  • physical exercise
  • blood pressure
  • Pelvic Floor
  • gestational hypertension
  • pre-eclampsia
  • small vessels
  • endothelial function
04

In context

Pre-Eclampsia Reclassified

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

This study's planned enrollment of 40 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.

Browse Pre-Eclampsia studies →

Lead sponsor

Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal is the lead sponsor of 34 studies on the registry; 16 are open to participants now.

Compared within Pre-Eclampsia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pregnancy-Induced. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • are 3 to 6 months postpartum, willing, and able to give for participation;
  • are more than 18 years old;
  • are able to access and use a computer, mobile phone and internet (for online sessions);
  • were diagnosed with GH (BP higher than 139/89 mmHg after 20 gestational weeks) or PE (BP higher than 139/89 mmHg and proteinuria after 20 gestational weeks) during pregnancy.

Exclusion criteria

Exclusion Criteria:

  • have chronic (pre-existing) hypertension (BP>139/89 mmHg pre-pregnancy, \<20 weeks' gestation or after 6 weeks postpartum);
  • received antihypertensive drug therapy prior to pregnancy or after 6 weeks postpartum;
  • are taking beta-blockers for any reason;
  • participated in exercise activity programs regularly before 3-month postpartum (more than 2 hour of moderate-to-vigorous exercise per week);
  • have any musculoskeletal injury that can limit or contraindicate the practice of exercise;
  • have any major to exercise such as cardiomyopathy, cardiac arrhythmias and conduction abnormalities or congenital heart disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Rehabilitation Group

    The rehabilitation Group will be submitted to an 8-week exercise and education program with a hybrid format, delivered by a professional physiotherapist at the Centre Jean-Jacques Gauthier (CJJG). Briefly, one in-person session (60 minutes of aerobic exercise and full-body strength exercise), one online session (30-35 minutes - focus on pelvic floor muscle training, core/abdominals, balance, and stretching exercises), and one pre-recorded video (30 minutes - exercise instructions) will be delivered per week. Participants will use Fitbit Charge-6 to progressively reach daily 10,000 steps throughout the intervention period. Four online educational workshops on healthy lifestyle will be delivered.

    Other: Postpartum Cardio-obstetric Rehabilitation Program

  • No intervention
    Control group

    Control group participants will received the usual care, together with information about the guidelines for physical activity practice, nutritional and risk factor monitoring instructions, pelvic floor exercise instructions, and recommendations to progressively reach daily 10,000 steps according to guidelines . Participants will also receive a Fitbit device.

Interventions

  • OtherPostpartum Cardio-obstetric Rehabilitation Program

    The intervention consists of an 8-week exercise and education program with a hybrid format (in person, virtual and pre-recorded sessions). The aerobic exercise intensity will progressively increase from 50 to 85% of Targeted Heart Rate Range (THRR), calculated for middle-aged women using the maximal heart rate (HR) estimated as 206 - (0.88 x age) . First and second weeks training will target an intensity of 50-65% THRR, third and fourth weeks will target 65 to 75% of THRR, fifth to seventh weeks will target 75 to 80%, and eighth week will target 85%. Participants will use Fitbit Charge-6 to monitor THRR during exercise sessions. Pelvic floor, body alignment/core stability, balance, and low back pain prevention exercises will be added to each in-person session and repeated during the online session. Participants from the intervention group will receive recommendations to progressively reach daily 10,000 steps throughout the intervention period.

07

What researchers measure

Primary outcomes

  1. Office Blood Pressure

    Resting office BP will be measured with the patient in the sitting position after 5 minutes at rest using a validated automated sphygmomanometer according to established practice guidelines . Three readings will be taken at intervals of 2 minutes.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  2. 24-hour Ambulatory Blood Pressure

    24-hour Ambulatory Blood Pressure using OSCAR 2 equipment.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

Secondary outcomes

  1. Static Retinal Vascular Analysis

    Retinal microvasculature imaging will be taken using Static Vessel Analyzer (SVA-T, Imedos) through non-invasive procedures described by Hanssen's team .

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  2. Peripheral artery stiffness - PWV

    Peripheral artery stiffness will be measured using SphygmoCor XCEL system through pulse wave velocity (PWV) as described by Daskalopoulou's team.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  3. Peripheral artery stiffness - PWA

    The Sphygmocor XCEL system will be used to assess arterial stiffness through Pulse Wave Analysis (PWA), according to the instruction guidelines.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  4. Physical capacity (6MWT)

    Six-minute walk test will be performed following the protocol described by the American Thoracic Society.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  5. Physical activity levels

    All participants will receive a wrist worn heart rate and accelerometer monitor (Fitbit Charge 6). This device will be used to monitor physical activity levels (total steps per week) and targeted heart rates during exercise training.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  6. Body composition

    Body composition will be measure using a bioimpedance scale InBody 570.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  7. Timed Up and Go (TUG)

    TUG test: The objective of TUG test is to assess mobility, balance and fall-risk. It consists of the participant stand-up from a chair, walk 3 meters, turn, walk back and sit down again. Interpretation: test performed ≤10 seconds indicates normal mobility.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  8. Handgrip strength

    The maximal handgrip strength will be performed using a manual Jamar Hydraulic Hand Dynamometer.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  9. Glucose

    Blood draw by venipuncture will be collected to measure glucose at the Biochemistry laboratory of the MUHC.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  10. Angiogenic and proliferative function of peripheral blood ECFCs

    Endothelial cell function will be assessed by the procedures described by Bertagnolli's team . ECFCs = Endothelial colony forming cell

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  11. Plasmatic levels of angiogenic factors - VEGF

    Serum concentration of angiogenic factors by ELISA following manufacturer instructions - Vascular endothelial growth factor (VEGF)

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  12. Heart rate variability

    R-R intervals will be recorded using a Vantage V2 Polar heart rate monitor at a sampling rate of 1,000 Hz. HRV will be recorded during deep breathing maneuver (continuous cycles) for 4 min in a supine position. HRV will be analyzed using Kubios HRV software following guidelines from the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  13. Circulating Endothelial Cells (cEC) Function

    cEC tube formation capacity on matrigel, proliferation, and migration capacities.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  14. Total cholesterol

    Blood draw by venipuncture will be collected to measure total cholesterol at the Biochemistry laboratory of the MUHC.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  15. Insuline

    Blood draw by venipuncture will be collected to measure total cholesterol at the Biochemistry laboratory of the MUHC.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  16. Glycated hemoglobin (HbA1c)

    Blood draw by venipuncture will be collected to measure HbA1c at the Biochemistry laboratory of the MUHC.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  17. LDL cholesterol

    Blood draw by venipuncture will be collected to measure LDL-cholesterol at the Biochemistry laboratory of the MUHC.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  18. HDL cholesterol

    Blood draw by venipuncture will be collected to measure HDL cholesterol at the Biochemistry laboratory of the MUHC.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  19. Triglycerides

    Blood draw by venipuncture will be collected to measure triglycerides at the Biochemistry laboratory of the MUHC.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  20. Brain Natriuretic Peptide (NT-PRO-BNP)

    Blood draw by venipuncture will be collected to measure NT-PRO-BNP at the Biochemistry laboratory of the MUHC.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  21. C-reactive protein (CRP)

    Blood draw by venipuncture will be collected to measure C-reactive protein (CRP) at the Biochemistry laboratory of the MUHC.

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  22. Plasmatic levels of angiogenic factors - NO

    Serum concentration of angiogenic factors by ELISA following manufacturer instructions - Nitric Oxide (NO).

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

Other outcomes

  1. SF-36 Quality of Life Questionnaire (SF-36).

    Health status will be evaluated based on: SF-36 Quality of Life Questionnaire (SF-36).

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  2. Patient Health Questionnaire-9 (PHQ-9)

    Health status will be evaluated based on: Patient Health Questionnaire-9 (PHQ-9) for depression symptoms

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  3. Edinburgh Postnatal Depression Scale (EPDS).

    Health status will be evaluated based on: Edinburgh Postnatal Depression Scale (EPDS).

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  4. Pittsburgh Sleep Quality Index (PSQI).

    Health status will be evaluated based on: Pittsburgh Sleep Quality Index (PSQI).

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  5. Pregnancy Physical Activity Questionnaire (PPAQ).

    Physical activity will be also evaluated based on Pregnancy Physical Activity Questionnaire (PPAQ).

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  6. Duke Activity Status Index (DASI)

    Physical activity will be also evaluated based on Duke Activity Status Index (DASI)

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  7. International Physical Activity Questionnaire (IPAQ).

    Physical activity will be also evaluated based on International Physical Activity Questionnaire (IPAQ).

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  8. Pelvic Floor Distress Inventory (PFDI-20)

    Pelvic health will be evaluated by Pelvic Floor Distress Inventory (PFDI-20)

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  9. Urogenital Distress Inventory (UDI)

    Pelvic health will be evaluated by Urogenital Distress Inventory (UDI).

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

  10. Pelvic Floor Impact Questionnaire (PFIQ-7).

    Pelvic health will be evaluated by Pelvic Floor Impact Questionnaire (PFIQ-7).

    Time frame: Baseline, immediately post-intervention, and 6-month post-intervention

08

Study locations

1 site
  • Hôpital du Sacre-Coer de Montréal - CIUSSS du Nord-de-l'Île-de-Montréal
    Montreal, Quebec, Canada
09

References and documents

Publications

  • Visser VS, Hermes W, Franx A, Koopmans CM, van Pampus MG, Mol BW, de Groot CJ. High blood pressure six weeks postpartum after hypertensive pregnancy disorders at term is associated with chronic hypertension. Pregnancy Hypertens. 2013 Oct;3(4):242-7. doi: 10.1016/j.preghy.2013.07.002. Epub 2013 Aug 9. PubMed 26103803 ↗
  • Phan K, Schiller I, Dendukuri N, Gomez YH, Gorgui J, El-Messidi A, Gagnon R, Daskalopoulou SS. A longitudinal analysis of arterial stiffness and wave reflection in preeclampsia: Identification of changepoints. Metabolism. 2021 Jul;120:154794. doi: 10.1016/j.metabol.2021.154794. Epub 2021 May 8. PubMed 33971204 ↗
  • Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014 Apr;4(2):105-45. doi: 10.1016/j.preghy.2014.01.003. Epub 2014 Feb 25. PubMed 26104418 ↗
  • Lampinen KH, Ronnback M, Kaaja RJ, Groop PH. Impaired vascular dilatation in women with a history of pre-eclampsia. J Hypertens. 2006 Apr;24(4):751-6. doi: 10.1097/01.hjh.0000217859.27864.19. PubMed 16531805 ↗
  • Davenport MH, Ruchat SM, Mottola MF, Davies GA, Poitras VJ, Gray CE, Garcia AJ, Barrowman N, Adamo KB, Duggan M, Barakat R, Chilibeck P, Fleming K, Forte M, Korolnek J, Nagpal T, Slater LG, Stirling D, Zehr L. 2019 Canadian Guideline for Physical Activity Throughout Pregnancy: Methodology. J Obstet Gynaecol Can. 2018 Nov;40(11):1468-1483. doi: 10.1016/j.jogc.2018.09.004. Epub 2018 Oct 18. No abstract available. PubMed 30343979 ↗
  • Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007 Nov 10;335(7627):974. doi: 10.1136/bmj.39335.385301.BE. Epub 2007 Nov 1. PubMed 17975258 ↗
  • Bertagnolli M, Nuyt AM, Thebaud B, Luu TM. Endothelial Progenitor Cells as Prognostic Markers of Preterm Birth-Associated Complications. Stem Cells Transl Med. 2017 Jan;6(1):7-13. doi: 10.5966/sctm.2016-0085. Epub 2016 Jul 27. PubMed 28170188 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for Aug 2026, 14 months later.

Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 14 months is below that.

Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
Apr 9, 2025
StartEst.
Jun 15, 2025
Primary completionEst.
Aug 30, 2026
CompletionEst.
Dec 30, 2026
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06920537
Lead sponsor
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Responsible party
Mariane Bertagnolli (Assistant Professor, Scientist, McGill University) — Principal investigator
First posted
Apr 9, 2025
Start date
Jun 15, 2025 (estimated)
Primary completion
Aug 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 14, 2025

Study contacts

Mariane Bertagnolli, PhD, Professor
Contact
mariane.bertagnolli.cnmtl@ssss.gouv.qc.ca
514-388-2222 ext. 2501
Rafael O Fernandes, PhD
Contact
rafael.fernandes@muhc.mcgill.ca

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion